APstem Pipeline

Market Potential & Priority

Regenerative Medicine

Regenerative medicine focuses on the regeneration or replacement of organs, tissues, and human cells to re-establish normal function.

The regenerative market is expected to reach $73.4 Billion by 2027, a dramatic increase from $13.3 Billion in 2019, expanding almost exponentially at a CAGR of 23.8%.

Our AHPSCs™ have high plasticity and therefore can become various types of cells in the human body giving them unlimited potential for Regenerative Medicine.

Non-Healing Wounds

Non-healing wounds affect more than 6 million people in the US each year. These wounds are chronic and are particularly difficult to treat, often leading to infections and amputation for many patients with diabetes and with vascular diseases.  There is an increasing incidence of diabetes and wound ulcers in our growing geriatric population.  This $10.34 Billion market is experiencing a CAGR of 4.5%.

Our AHPSCs™ can regenerate new skin from wounds including producing dermal appendages (sebaceous glands, smooth muscle) and new hair follicles.

Liver Disease

Chronic liver disease and cirrhosis are major causes of morbidity and mortality in the US, with continuously growing prevalence primarily driven by a significant increase in non-alcoholic fatty liver disease and its sub-type, nonalcoholic steatohepatitis which are often related to obesity, high cholesterol and type 2 diabetes. Direct medical costs of over $103 Billion each year go to treating the 75-100 million Americans with these liver diseases.

Our AHPSCs™ can regenerate functional hepatocytes to repopulate the liver and reconstruct blood circulation, therefore can repair acute and chronic liver damages.